159 related articles for article (PubMed ID: 38055623)
1. IL-2 produced by HBV-specific T cells as a biomarker of viral control and predictor of response to PD-1 therapy across clinical phases of chronic hepatitis B.
Chua C; Salimzadeh L; Ma AT; Adeyi OA; Seo H; Boukhaled GM; Mehrotra A; Patel A; Ferrando-Martinez S; Robbins SH; La D; Wong D; Janssen HLA; Brooks DG; Feld JJ; Gehring AJ
Hepatol Commun; 2023 Dec; 7(12):. PubMed ID: 38055623
[TBL] [Abstract][Full Text] [Related]
2. OX40 stimulation and PD-L1 blockade synergistically augment HBV-specific CD4 T cells in patients with HBeAg-negative infection.
Jacobi FJ; Wild K; Smits M; Zoldan K; Csernalabics B; Flecken T; Lang J; Ehrenmann P; Emmerich F; Hofmann M; Thimme R; Neumann-Haefelin C; Boettler T
J Hepatol; 2019 Jun; 70(6):1103-1113. PubMed ID: 30826436
[TBL] [Abstract][Full Text] [Related]
3. Diverse facets of MDSC in different phases of chronic HBV infection: Impact on HBV-specific T-cell response and homing.
Pal S; Dey D; Chakraborty BC; Nandi M; Khatun M; Banerjee S; Santra A; Ghosh R; Ahammed SM; Chowdhury A; Datta S
Hepatology; 2022 Sep; 76(3):759-774. PubMed ID: 35000202
[TBL] [Abstract][Full Text] [Related]
4. [Hepatitis B e antigen from chronic hepatitis B patients induces Th1/Th2 cytokine imbalance in vitro].
Han YP; Li J; Jiang LF; Xu QQ; Liu B; Dong L; Chen N; Kong LH; Xie FR; Huang ZH
Zhonghua Gan Zang Bing Za Zhi; 2013 Aug; 21(8):584-9. PubMed ID: 24119737
[TBL] [Abstract][Full Text] [Related]
5. Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B.
Fisicaro P; Valdatta C; Massari M; Loggi E; Biasini E; Sacchelli L; Cavallo MC; Silini EM; Andreone P; Missale G; Ferrari C
Gastroenterology; 2010 Feb; 138(2):682-93, 693.e1-4. PubMed ID: 19800335
[TBL] [Abstract][Full Text] [Related]
6. Peginterferon-α does not improve early peripheral blood HBV-specific T-cell responses in HBeAg-negative chronic hepatitis.
Penna A; Laccabue D; Libri I; Giuberti T; Schivazappa S; Alfieri A; Mori C; Canetti D; Lampertico P; Viganò M; Colombo M; Loggi E; Missale G; Ferrari C
J Hepatol; 2012 Jun; 56(6):1239-46. PubMed ID: 22326467
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis B Virus--Specific and Global T-Cell Dysfunction in Chronic Hepatitis B.
Park JJ; Wong DK; Wahed AS; Lee WM; Feld JJ; Terrault N; Khalili M; Sterling RK; Kowdley KV; Bzowej N; Lau DT; Kim WR; Smith C; Carithers RL; Torrey KW; Keith JW; Levine DL; Traum D; Ho S; Valiga ME; Johnson GS; Doo E; Lok AS; Chang KM;
Gastroenterology; 2016 Mar; 150(3):684-695.e5. PubMed ID: 26684441
[TBL] [Abstract][Full Text] [Related]
8. Functional Exhaustion of HBV-Specific CD8 T Cells Impedes PD-L1 Blockade Efficacy in Chronic HBV Infection.
Ferrando-Martinez S; Snell Bennett A; Lino E; Gehring AJ; Feld J; Janssen HLA; Robbins SH
Front Immunol; 2021; 12():648420. PubMed ID: 34589081
[TBL] [Abstract][Full Text] [Related]
9. Combined blockade of programmed death-1 and activation of CD137 increase responses of human liver T cells against HBV, but not HCV.
Fisicaro P; Valdatta C; Massari M; Loggi E; Ravanetti L; Urbani S; Giuberti T; Cavalli A; Vandelli C; Andreone P; Missale G; Ferrari C
Gastroenterology; 2012 Dec; 143(6):1576-1585.e4. PubMed ID: 22929808
[TBL] [Abstract][Full Text] [Related]
10.
Sung PS; Park DJ; Kim JH; Han JW; Lee EB; Lee GW; Nam HC; Jang JW; Bae SH; Choi JY; Shin EC; Park SH; Yoon SK
Front Immunol; 2019; 10():1319. PubMed ID: 31244857
[TBL] [Abstract][Full Text] [Related]
11. Restoration of HBV-specific CD8
Wang D; Fu B; Shen X; Guo C; Liu Y; Zhang J; Sun R; Ye Y; Li J; Tian Z; Wei H
Signal Transduct Target Ther; 2021 Nov; 6(1):376. PubMed ID: 34737296
[TBL] [Abstract][Full Text] [Related]
12. HBV-specific lymphoproliferative and cytokine responses in patients with chronic hepatitis B.
Vingerhoets J; Michielsen P; Vanham G; Bosmans E; Paulij W; Ramon A; Pelckmans P; Kestens L; Leroux-Roels G
J Hepatol; 1998 Jan; 28(1):8-16. PubMed ID: 9537868
[TBL] [Abstract][Full Text] [Related]
13. Programmed death 1 expression during antiviral treatment of chronic hepatitis B: Impact of hepatitis B e-antigen seroconversion.
Evans A; Riva A; Cooksley H; Phillips S; Puranik S; Nathwani A; Brett S; Chokshi S; Naoumov NV
Hepatology; 2008 Sep; 48(3):759-69. PubMed ID: 18697210
[TBL] [Abstract][Full Text] [Related]
14. Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: A pilot study.
Gane E; Verdon DJ; Brooks AE; Gaggar A; Nguyen AH; Subramanian GM; Schwabe C; Dunbar PR
J Hepatol; 2019 Nov; 71(5):900-907. PubMed ID: 31306680
[TBL] [Abstract][Full Text] [Related]
15. Augmentation of hepatitis B virus-specific cellular immunity with programmed death receptor-1/programmed death receptor-L1 blockade in hepatitis B virus and HIV/hepatitis B virus coinfected patients treated with adefovir.
Sherman AC; Trehanpati N; Daucher M; Davey RT; Masur H; Sarin SK; Kottilil S; Kohli A
AIDS Res Hum Retroviruses; 2013 Apr; 29(4):665-72. PubMed ID: 23259453
[TBL] [Abstract][Full Text] [Related]
16. HBeAg seroconversion is associated with a more effective PD-L1 blockade during chronic hepatitis B infection.
Ferrando-Martinez S; Huang K; Bennett AS; Sterba P; Yu L; Suzich JA; Janssen HLA; Robbins SH
JHEP Rep; 2019 Sep; 1(3):170-178. PubMed ID: 32039367
[TBL] [Abstract][Full Text] [Related]
17. Restoration of HBV-specific CD8+ T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation.
Bengsch B; Martin B; Thimme R
J Hepatol; 2014 Dec; 61(6):1212-9. PubMed ID: 25016223
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B.
Rinker F; Zimmer CL; Höner Zu Siederdissen C; Manns MP; Kraft ARM; Wedemeyer H; Björkström NK; Cornberg M
J Hepatol; 2018 Sep; 69(3):584-593. PubMed ID: 29758333
[TBL] [Abstract][Full Text] [Related]
19. PD-1 blockage reverses immune dysfunction and hepatitis B viral persistence in a mouse animal model.
Tzeng HT; Tsai HF; Liao HJ; Lin YJ; Chen L; Chen PJ; Hsu PN
PLoS One; 2012; 7(6):e39179. PubMed ID: 22761734
[TBL] [Abstract][Full Text] [Related]
20. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues.
Boni C; Laccabue D; Lampertico P; Giuberti T; Viganò M; Schivazappa S; Alfieri A; Pesci M; Gaeta GB; Brancaccio G; Colombo M; Missale G; Ferrari C
Gastroenterology; 2012 Oct; 143(4):963-73.e9. PubMed ID: 22796241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
